Compare · NVO vs RNAC
NVO vs RNAC
Side-by-side comparison of Novo Nordisk A/S (NVO) and Cartesian Therapeutics Inc. (RNAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RNAC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.64B, about 1017.5x RNAC ($188.3M).
- Over the past year, NVO is down 40.8% and RNAC is down 36.5% - RNAC leads by 4.3 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 3 for RNAC).
- NVO has more recent analyst coverage (25 ratings vs 9 for RNAC).
- Company
- Novo Nordisk A/S
- Cartesian Therapeutics Inc.
- Price
- $42.01-2.10%
- $6.28-2.48%
- Market cap
- $191.64B
- $188.3M
- 1M return
- -5.38%
- -9.31%
- 1Y return
- -40.76%
- -36.50%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 11
- 3
- Recent ratings
- 25
- 9
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest RNAC
- Cartesian Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
- Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
- Amendment: SEC Form SCHEDULE 13G/A filed by Cartesian Therapeutics Inc.
- Cartesian Therapeutics Announces New Employment Inducement Grants
- SEC Form S-8 filed by Cartesian Therapeutics Inc.
- SEC Form 10-Q filed by Cartesian Therapeutics Inc.
- Cartesian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
- SEC Form DEF 14A filed by Cartesian Therapeutics Inc.